(Q39796282)

14 September 2017

Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy (English)

1 reference

14 September 2017

Stephen E F Spurgeon

1

1 reference

14 September 2017

Solange Mongoue-Tchokote

2

1 reference

14 September 2017

Lauren Collins

3

1 reference

14 September 2017

Ryan Priest

4

1 reference

14 September 2017

Yi-Ching Hsieh

5

1 reference

14 September 2017

Laura M Peters

6

1 reference

14 September 2017

Tomasz M Beer

7

1 reference

14 September 2017

Motomi Mori

8

1 reference

14 September 2017

Mark Garzotto

9

1 reference

14 September 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

14 September 2017

1 reference

14 September 2017

69

1 reference

14 September 2017

5

1 reference

14 September 2017

931-935

1 reference

The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Determinants of Prostate Cancer Specific Survival Following Radiation Therapy During the Prostate Specific Antigen Era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Novel artificial neural network for early detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

Improved detection of prostate cancer using classification and regression tree analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.01.075

10.1016/J.UROLOGY.2007.01.075

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference